# Pharmacokinetics, Safety and Tolerability of Escalating Rifapentine Doses in Healthy Volunteers

> **NCT01162486** · PHASE1 · COMPLETED · sponsor: **Johns Hopkins University** · enrollment: 37 (actual)

## Conditions studied

- Tuberculosis
- Tuberculosis, Pulmonary

## Interventions

- **DRUG:** Rifampin & midazolam
- **DRUG:** rifapentine & midazolam
- **DRUG:** rifapentine & midazolam
- **DRUG:** rifapentine & midazolam
- **DRUG:** rifapentine and midazolam
- **DRUG:** rifapentine and midazolam

## Key facts

- **NCT ID:** NCT01162486
- **Lead sponsor:** Johns Hopkins University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-04
- **Primary completion:** 2011-02
- **Final completion:** 2011-03
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2019-05-07

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01162486

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01162486, "Pharmacokinetics, Safety and Tolerability of Escalating Rifapentine Doses in Healthy Volunteers". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01162486. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*